Event-Driven Stocks

Myrexis, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs2 warningdetails ↓

Financials

SEC XBRL · annual
 FY13FY12FY11FY10
Revenue$185,000$90,000
Operating income−$3.2M−$31.8M−$40.5M−$48.1M
Net income−$3.2M−$31.2M−$38.7M−$47.0M
Total assets$1.2M$91.7M$121.3M
Total liabilities
Equity$1.2M$89.4M$118.0M$149.9M
EPS (diluted)
Shares out.34.5M26.8M26.1M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2013
Operating margin
Net margin
Return on equity
−278.4%
Return on assets
−261.8%
Return on capital (ROCE)
−276.1%
Liabilities / assets
Debt / equity
Book value / share
$0.03
Revenue growth (YoY)
Net income growth (YoY)

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2013
Accruals / assets
786.9%high accruals
Piotroski F-Score
0/6weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
42
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 0Financial strength 100

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →

Signs

2 warning0 good
  • Negative operating cash flow
  • High accruals — earnings-quality risk

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Insider transactions

SEC Form 4 · most recent
7 acquisitions5 disposals5 open-market buy(s)net +366,135 shares · last 12
InsiderDateTypeSharesPrice
Couchman Jonathan10% ownerAug 13, 2021Sell50,000$0.39
Couchman Jonathan10% ownerAug 24, 2020Sell52,100$0.18
Couchman Jonathan10% ownerAug 5, 2020Buy506,292$0.20
Henderson John TDirectorJan 18, 2013Option exercise7,500$1.07
First Eagle Investment Management, Llc10% ownerNov 2, 2012Sell42,000$2.38
First Eagle Investment Management, Llc10% ownerNov 1, 2012Sell35,000$2.37
Kendell AndreaOfficer — Chief Financial OfficerSep 25, 2012Sell693$2.34
Kendell AndreaOfficer — Chief Financial OfficerJul 2, 2012Grant20,000$0.00
Aryeh JasonDirectorJun 18, 2012Buy3,000$2.29
Aryeh JasonDirectorJun 14, 2012Buy4,000$2.36
Aryeh JasonDirectorJun 7, 2012Buy1,116$2.40
Aryeh JasonDirectorMay 30, 2012Buy4,020$2.46

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Corporate family

Spun off from Myriad GeneticsMYGN · Jun 30, 2009

From the spin-off filings we track. Follow a company to walk its own history.

Event-driven situations (2)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.